<!doctype html>
<html lang="es">
<head>
<meta charset="utf-8" />
<meta name="viewport" content="width=device-width, initial-scale=1" />
<title>Spanish Daily – Dec 19, 2025</title>
<meta name="color-scheme" content="light" />
<style>
  :root { --maxw: 800px; color-scheme: light; }
  html { -webkit-text-size-adjust: 100%; }
  body {
    margin: 0;
    padding: 0;
    background-color: #ffffff;
    color: #111111;
    font-family: system-ui,-apple-system,Segoe UI,Roboto,Helvetica,Arial,sans-serif,Apple Color Emoji,Segoe UI Emoji;
    line-height: 1.6;
    font-size: 18px;
  }
  header, main, footer { max-width: var(--maxw); margin: 0 auto; padding: 16px; }
  header { padding-top: 20px; }
  h1 { font-size: 1.4rem; margin: 0 0 8px; }
  .subtle { opacity: 0.72; font-size: 0.95rem; }
  .card { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 14px; margin: 12px 0; }
  .tip-word { all: unset; display: inline; position: relative; cursor: pointer;
    text-decoration: underline dotted; text-underline-offset: 3px;
    padding: 0 .1em; border-radius: .35em; background: rgba(255,235,59,.28); }
  .tooltip { position: fixed; padding: .48rem .6rem; background: rgba(0,0,0,.88); color: #fff;
    border-radius: .55rem; font-size: .95rem; line-height: 1.3; max-width: min(90vw, 26rem);
    z-index: 9999; box-shadow: 0 6px 18px rgba(0,0,0,.18); }
  .content { white-space: pre-line; }
  .card { margin-bottom: 1.5em; line-height: 1.6; }
  strong { display: inline-block; margin-top: .35em; }
  details { border: 1px solid rgba(0,0,0,0.08); border-radius: 12px; padding: 12px; }
  details + details, details + .card { margin-top: 12px; }
  summary { cursor: pointer; font-weight: 600; }
  summary::marker { content: ""; }
  summary::after { content: " ▸"; }
  details[open] summary::after { content: " ▾"; }
  .debug { position: fixed; bottom: 8px; right: 8px; font-size: 12px; opacity: .6; }
</style>
</head>
<body>
  <header>
    <h1>Spanish Daily</h1>
    <div class="subtle">Toca una palabra subrayada para ver la traducción. Toca fuera para cerrar.</div>
  </header>

  <main>
    <!-- Spanish first -->
    <section class="card content">
STORY

<span title="Lecanemab is a disease-modifying therapy">Lecanemab es una terapia modificadora de la enfermedad</span> para el <span title="early Alzheimer’s">Alzheimer temprano</span>. <span title="It requires solid planning">Requiere una planificación sólida</span> para <span title="its safe use">su uso seguro</span>. <span title="Doctors must offer rapid access">Los médicos deben ofrecer acceso rápido</span>, pero también <span title="monitor safety and system limits">vigilar la seguridad y los límites del sistema</span>, ya que <span title="its use will increase">su uso aumentará</span> en <span title="2024 to 2025">2024–2025</span>.

<span title="Referral criteria">Criterios de derivación</span>: <span title="Use only in mild cognitive impairment">Usar solo en deterioro cognitivo leve</span> (DCL) <span title="due to Alzheimer’s disease">debido a enfermedad de Alzheimer</span> o <span title="mild dementia">demencia leve</span> <span title="with confirmed amyloid pathology">con patología amiloide confirmada</span>. <span title="Use in adults who still maintain good daily functioning">Usar en adultos que aún mantienen buen funcionamiento diario</span>.

<span title="Initial assessment">Evaluación inicial</span>: <span title="Perform a detailed cognitive assessment">Realizar una evaluación cognitiva detallada</span>. <span title="Do an MRI">Hacer una resonancia magnética</span> (RM) <span title="within 12 months">dentro de los 12 meses</span>. <span title="Review for microhemorrhages">Revisar si hay microhemorragias</span>, macrohemorragias, <span title="superficial siderosis">siderosis superficial</span> o <span title="severe small vessel disease">enfermedad severa de pequeños vasos</span>. <span title="Consider APOE genotyping">Considerar la genotipificación de APOE</span> <span title="to assess the risk of ARIA">para evaluar el riesgo de ARIA</span>.

<span title="Infusion logistics">Logística de infusión</span>: <span title="The dose is 10 mg per kg">La dosis es de 10 mg/kg</span> <span title="by intravenous route">por vía intravenosa</span> <span title="every 2 weeks">cada 2 semanas</span> <span title="for about 1 hour">durante aproximadamente 1 hora</span>. <span title="Sufficient availability of infusion chairs is needed">Se necesita suficiente disponibilidad de sillones de infusión</span>, <span title="blood pressure protocols">protocolos de presión arterial</span> y <span title="same-day acute care">atención aguda el mismo día</span> <span title="for hypersensitivity or infusion reactions">para reacciones de hipersensibilidad o a la infusión</span>.

<span title="Monitoring and management of ARIA">Monitoreo y manejo de ARIA</span>: <span title="Most cases of ARIA-E occur">La mayoría de los casos de ARIA-E ocurren</span> <span title="in the first months">en los primeros meses</span>. <span title="Do MRI at the start">Realizar RM al inicio</span> y <span title="frequently in the first 6–7 months">con frecuencia en los primeros 6–7 meses</span>, y <span title="immediately if new headaches, confusion, visual symptoms, or focal deficits appear">de inmediato si aparecen nuevos dolores de cabeza, confusión, síntomas visuales o déficits focales</span>. <span title="Mild and asymptomatic ARIA">La ARIA leve y asintomática</span> <span title="may allow a brief suspension of the dose">puede permitir una breve suspensión de la dosis</span> y <span title="close follow-up with MRI">seguimiento cercano con RM</span>. <span title="Moderate to severe or symptomatic ARIA">La ARIA moderada a severa o sintomática</span> <span title="usually requires suspension of treatment">suele requerir suspensión del tratamiento</span>, <span title="possible use of steroids">posible uso de esteroides</span> y <span title="neurology support">apoyo de neurología</span>.

<span title="Access restrictions">Restricciones de acceso</span>: <span title="CMS coverage requires participation in a registry">La cobertura de CMS requiere participación en un registro</span> y <span title="diagnosis records">registros de diagnóstico</span>, <span title="amyloid confirmation">confirmación amiloide</span> y <span title="monitoring">monitoreo</span>. <span title="Centers must use standardized referral forms">Los centros deben usar formularios de derivación estandarizados</span> y <span title="electronic orders">órdenes electrónicas</span>.

<span title="Complementary or alternative options">Opciones complementarias alternativas</span>: <span title="If infusion, MRI, or monitoring are difficult">Si la infusión la RM o el monitoreo son difíciles</span>, <span title="work on vascular risk factors">trabajar en los factores de riesgo vascular</span>, <span title="use cholinesterase inhibitors or memantine when appropriate">usar inhibidores de colinesterasa memantina cuando corresponda</span> y <span title="refer to clinical trials">derivar a ensayos clínicos</span>.

<span title="For practice">Para la práctica</span>: <span title="In 2024–2025, use Lecanemab in structured specialized programs">En 2024–2025 usar Lecanemab en programas especializados estructurados</span> <span title="with clear referral rules">con reglas claras de derivación</span>, <span title="defined infusion and MRI plans">planes definidos de infusión y RM</span>, y <span title="support for symptomatic care and trial options">respaldo de atención sintomática y opciones de ensayos</span> <span title="when constant monitoring cannot be guaranteed">cuando no se pueda garantizar un monitoreo constante</span>.

---
DIALOGUE

Narrator: <span title="Today, Dr. Kim talks with Mrs. Lee about a new treatment for Alzheimer’s">Hoy la Dra. Kim habla con la Sra. Lee sobre un nuevo tratamiento para el Alzheimer</span>.
Physician: <span title="Hello Mrs. Lee">Hola Sra. Lee</span>. <span title="We found early Alzheimer’s disease in your tests">Encontramos enfermedad de Alzheimer temprana en sus exámenes</span>.
Patient: <span title="Yes doctor">Sí doctora</span>. <span title="I forget things but I still do most things at home">Olvido cosas pero todavía hago la mayoría de las cosas en casa</span>.
Physician: <span title="There is a new medicine called Lecanemab">Hay un nuevo medicamento llamado Lecanemab</span>. <span title="It can slow the disease">Puede ralentizar la enfermedad</span>.
Patient: <span title="How does this medicine work for me">¿Cómo funciona este medicamento para mí</span>?
Physician: <span title="Lecanemab acts on the amyloid in your brain">Lecanemab actúa sobre el amiloide en su cerebro</span>. <span title="You must receive an intravenous infusion every two weeks">Debe recibir una infusión intravenosa cada dos semanas</span>.
Patient: <span title="Are there risks or side effects">¿Hay riesgos o efectos secundarios</span>?
Physician: <span title="Sometimes people have headaches or confusion">A veces las personas tienen dolor de cabeza o confusión</span>. <span title="We monitor with MRIs">Vigilamos con resonancias magnéticas</span>.
Patient: <span title="How often do I need the MRIs">¿Con qué frecuencia necesito las resonancias</span>?
Physician: <span title="Frequently in the first six months">Frecuentemente en los primeros seis meses</span>, <span title="then less if there are no problems">luego menos si no hay problemas</span>.
Patient: <span title="Can I start soon">¿Puedo empezar pronto</span>?
Physician: <span title="First you need more tests like an MRI">Primero necesita más exámenes como una resonancia</span>. <span title="We check if Lecanemab is safe for you">Verificamos si Lecanemab es seguro para usted</span>.
Patient: <span title="Thank you doctor">Gracias doctora</span>. <span title="I want to try it if it can help me">Quiero intentarlo si puede ayudarme</span>.
    </section>

    <!-- English below -->

    <details open class="card content">
      <summary>INGLÉS</summary>
STORY

Lecanemab is a disease-modifying therapy for early Alzheimer’s disease. It needs strong planning for safe use. Clinicians must give fast access but also watch safety and system limits, as use grows in 2024–2025.

Referral criteria: Use only for mild cognitive impairment (MCI) due to Alzheimer’s disease or mild dementia with confirmed amyloid pathology. Use in adults who still have good daily function.

Baseline workup: Do detailed cognitive assessment. Do MRI within 12 months. Check for microhemorrhages, macrohemorrhage, superficial siderosis, or severe small-vessel disease. Think about APOE genotyping to check ARIA risk.

Infusion logistics: Dose is 10 mg/kg IV every 2 weeks over about 1 hour. You need enough infusion chairs, blood pressure protocols, and same-day acute care for hypersensitivity or infusion reactions.

ARIA monitoring and managing ARIA: Most ARIA-E happens in the first months. Do MRI at baseline and often in the first 6–7 months, and fast if new headache, confusion, visual symptoms, or focal deficits start. Mild, asymptomatic ARIA may allow short dose stop and close MRI. Moderate–severe or symptomatic ARIA often needs treatment stop, possible steroids, and neurology help.

Access constraints: CMS coverage needs registry participation and records of diagnosis, amyloid confirmation, and monitoring. Centers should use standard referral forms and electronic order sets.

Companion/alternative options: If infusion, MRI, or monitoring are hard, work on vascular risk factors, use cholinesterase inhibitors/memantine when right, and refer to clinical trials.

For practice: In 2024–2025, use Lecanemab in structured specialist programs with clear referral rules, set infusion and MRI plans, and backup symptomatic care and trial options when you cannot give steady monitoring.

---
DIALOGUE

Narrator: Today, Dr. Kim talks with Mrs. Lee about a new Alzheimer’s treatment.
Physician: Hello, Mrs. Lee. We found early Alzheimer’s disease in your tests.
Patient: Yes, doctor. I forget things but still do most things at home.
Physician: There is a new medicine called Lecanemab. It may slow the disease.
Patient: How does this medicine work for me?
Physician: Lecanemab targets amyloid in your brain. You must have an IV every two weeks.
Patient: Are there any risks or side effects?
Physician: Sometimes, people get headache or confusion. We watch with MRI scans.
Patient: How often do I need MRI scans?
Physician: Often in the first six months, then less after, if no problems.
Patient: Can I start soon?
Physician: First, you need more tests, like an MRI. We check if Lecanemab is safe for you.
Patient: Thank you, doctor. I want to try if it can help me.
    </details>
  </main>

  <footer class="subtle">
    <div>© Dec 19, 2025 · Mezra.AI · Practica todos los días.</div>
  </footer>

  <div class="debug">EN: found</div>

  <!-- NEW: light cache-busting helper -->
  <script>
  (function() {
    // 1. Get the version tag from the URL, if present (?v=SHA...)
    var params = new URLSearchParams(window.location.search);
    var version = params.get('v');

    // 2. Read the debug indicator already inside your page
    var debug = document.querySelector('.debug');
    var debugText = debug ? debug.textContent.trim() : '';

    // 3. Heuristic: if version is missing or debug looks suspicious, force a one-time reload
    var isLikelyStale =
      !version ||
      debugText === '' ||
      debugText.indexOf('placeholder') !== -1 ||
      debugText.indexOf('not found') !== -1 ||
      debugText.length < 3;

    if (isLikelyStale) {
      if (!params.get('forceReload')) {
        params.set('forceReload', '1');
        var newUrl = window.location.pathname + '?' + params.toString();
        window.location.replace(newUrl);
      }
    }
  })();
  </script>

  <!-- Existing tooltip behavior -->
  <script>
  (function () {
    document.querySelectorAll('.content').forEach(function(container) {
      container.querySelectorAll('span[title]').forEach(function(span) {
        var text = span.textContent;
        var tip  = span.getAttribute('title');
        var btn  = document.createElement('button');
        btn.className = 'tip-word'; btn.type = 'button';
        btn.textContent = text; btn.setAttribute('data-tip', tip);
        span.replaceWith(btn);
      });
    });

    var openTip = null;
    function closeTip(){ if(openTip){ openTip.remove(); openTip = null; } }
    function showTip(target){
      closeTip();
      var tipText = target.getAttribute('data-tip') || '';
      if(!tipText) return;
      var bubble = document.createElement('div');
      bubble.className = 'tooltip';
      bubble.textContent = tipText;
      document.body.appendChild(bubble);
      var r = target.getBoundingClientRect();
      var m = 8, vw = innerWidth, vh = innerHeight;
      var rect = bubble.getBoundingClientRect();
      var tw = rect.width;
      var th = rect.height;
      var left = r.left, top = r.bottom + m;
      if (left + tw + m > vw) left = Math.max(m, vw - tw - m);
      if (left < m) left = m;
      if (top + th + m > vh) top = Math.max(m, r.top - th - m);
      bubble.style.left = left + 'px';
      bubble.style.top  = top + 'px';
      openTip = bubble;
    }

    document.addEventListener('click', function(e) {
      var word = e.target.closest('.tip-word');
      if (word){ if (openTip) closeTip(); else showTip(word); e.stopPropagation(); }
      else { closeTip(); }
    });
    document.addEventListener('touchstart', function(e) {
      if (!e.target.closest('.tip-word')) closeTip();
    }, { passive: true });
    addEventListener('scroll', closeTip, { passive: true });
    addEventListener('resize', closeTip);
    document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeTip(); });
  })();
  </script>
</body>
</html>